| Literature DB >> 25707057 |
Karen W Jeng, Caroline R Baumal, Andre J Witkin, Steve R Witkin, Torsten W Wiegand, Nadia K Waheed.
Abstract
Ocriplasmin is a recombinant protease approved as a nonsurgical treatment for vitreomacular traction (VMT) and small macular holes with vitreomacular adhesion (VMA). Successful ocriplasmin treatment in clinical studies has been defined as nonsurgical resolution of VMA as demonstrated on optical coherence tomography (OCT) by day 28 after intravitreal injection. This report presents three eyes with improvement in visual acuity and clinical symptoms despite only partial release of VMT over 28 days after ocriplasmin injection. Copyright 2015, SLACK Incorporated.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25707057 DOI： 10.3928/23258160-20150213-02
Source DB: PubMed Journal: Ophthalmic Surg Lasers Imaging Retina ISSN： 2325-8160 Impact factor: 1.300